We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Synergy Hlth. | SYR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 2,325.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2,325.00 | 2,325.00 |
| Top Posts |
|---|
Posted at 08/2/2013 19:12 by analyst Investors Chronicle says SellShares in cleaning and sterilisation specialist Synergy Health (SYR) have been notably strong performers lately, outpacing shares in similar companies by 20 per cent over the past quarter on the back of some promising deals in new markets. True, Synergy almost certainly has a solid future in its key markets, but, in the medium-term, the share rating has moved too far ahead of the group's growth prospects. Really brave punters might try 'short selling' the stock; meanwhile, shareholders might simply opt to sell. The trigger for the big share-price move was Synergy's decisive entry into the US hospitals market. The acquisition of SRI/Surgical Express, in particular, for $25m (£17m) got the City's admiration, especially because the price paid looked good for a business generating sales of more than $100m. However, it is not clear what effect the expansion will have on Synergy's underlying profit margins. These were more than 15 per cent in the first half of 2012-13, but there is a risk that the peculiarities of the US business could eat into them. This is because most US hospitals, unlike those in Synergy's core business with the NHS, have their own sterilising and cleansing facilities on-site. That means Synergy would be paid a fee as a service provider, rather than as a more lucrative full-facility operator. There is no doubt that the US market is far larger than anything Synergy has entered so far and the opportunities are there. However, the question hanging over the States-side project is whether investors have taken into account the amount of investment needed over the next few years to bring the service up to Synergy's standards. That could generate big one-off costs that may not be adequately priced in. As support services businesses go, Synergy is unusual because a lot of its capital is tied up in tangible assets. That's because often it has to fund and build hospital cleaning facilities itself for the contracts it wins. That means lots of upfront spending in order to grow sales, as each new contract can mean another round of construction. Analysts at broker CanaccordGenuity estimate that to achieve an adequate cashflow return on its capital of around 8 per cent, the company must invest between £15m and £30m annually to generate the required income. This inhibits shareholders' returns as the lead time between winning a contract and starting operations is between 18 months to two years. CanaccordGenuity estimates that the company will clock up capital spending of £75m over the next three years. Given the lag between spending and revenue-generation, sales growth will be deferred, making Synergy much more cyclical than is generally perceived. Synergy also has its share of immediate problems resulting from austerity in the European Union. This affects its Dutch business supplying hospital linen, in particular. Meanwhile, a spending squeeze in the NHS, while not affecting existing contracts due to the importance for patient care, could slow the pipeline of new work that Synergy could bid for. Share tip summary Trading on almost 17 times forecast underlying earnings, Synergy's shares are rated just above the UK average for the healthcare services sector at a time when significant parts of its operations face slowing growth in its established markets. Granted, expansion into the US seems like a good move given the size of the market, and European austerity will not last for ever. Yet the rating has moved to a level that is vulnerable to correction if the company fails to outperform the market's expectations. Given the consistently high capital spending Synergy must undertake, the possibility of disappointment is higher than average. Sell. |
Posted at 07/6/2012 08:04 by hyper ai rolling overtime to fade as investors realise aquisition-led growth has to stop one day |
Posted at 05/6/2008 09:51 by dnevets "5 June 2008 SYNERGY HEALTHCARE PLCNotification of proposed AIM cancellation and Admission to the Official List Synergy today announces that it intends to apply for admission of its ordinary share capital to the Official List of the UK Listing Authority and to trading on the London Stock Exchange's market for listed securities. Since inception Synergy has grown both organically and through acquisitions, becoming increasingly diversified geographically. The Directors believe that this should now be reflected in the market on which Synergy shares are traded. Furthermore, the Directors believe that this move to the Official List will leave the Company well placed to achieve greater liquidity in its shares, raise its profile both domestically and internationally with investors and its customer base, and improve access to capital...." |
Posted at 10/6/2007 14:42 by johnrxx99 Not recently worst luck. They are still in the Momentum Investor portfolio. |
Posted at 23/11/2005 11:14 by johnrxx99 A nice set of results:-Synergy Healthcare H1 profit up 48 pct LONDON (AFX) - Synergy Healthcare PLC, which supplies of surgical and patient support services to hospitals in the UK and the Netherlands, has turned in a 48 pct rise in first-half profits thanks to strong organic sales growth across its operations. Pretax profit rose to 5.0 mln stg from 3.4 mln stg previously, while sales rose 75 pct to 50.4 mln stg Dr Richard Steeves, chief executive of Synergy, said: "Looking forward, the development of wider support services for patients together with our surgical developments in the UK and Netherlands should see the group continue to sustain its consistent track record of growth and profitability." The group will pay an interim dividend of 2.0 pence per share, an increase of 18 pct. tc Although this year has not been exciting, the company has done well and when the recent purchase is fully embedded it will go a lot further imo, dyor. Momentum Investor are still a holder. |
Posted at 08/12/2004 10:12 by noshy Nice piece in "The Momentum Investor", December issue."We first tipped SYR at its float and it has paid off spades. That said, the shares have a lot more mileage for those willing take a 2-3 year view, particularly as its burgeoning cashflows are more than capable of financing a much more aggressive aquisition programme." "Buy on dips" I've topped up today nosh |
Posted at 13/1/2004 08:06 by shuisky Hi slim, the rolling adjusted diluted EPS = 11.52p, which means the rolling PER=262/11.52= 22.7Interimn to interim EPS growth was 55% (adjusted diluted) . Let's take your figure of 25% eps growth, this translates to a PEG of 22.7/25%=.9 That's cheap. I appreciate punters want to take profits-it's natural, but investors should not lose perspective here. This has got far further to run. |
Posted at 07/9/2001 22:11 by cymro Tipped in Investors Chronicle today:Hospitals are increasingly moving towards the process of outsourcing their requirements. Recent AIM float Synergy Healthcare looks well placed to benefit cymro |
Posted at 31/8/2001 08:34 by analyst A blue share at over £2 offer price in a sea of red on the back of this:INVESTORS CHRONICLE Small Company Tips Synergy Healthcare Friday 31 Aug 2001 BUY BULL POINTS Solid track record and exposed to growth markets Group expected to win new contracts BEAR POINTS Rating is relatively high Shares tightly held by founders and institutions |
Posted at 19/8/2001 19:41 by 6million dollarman Latest News:LONDON (AFX) - Synergy Healthcare PLC proved fund managers still have an appetite for new equity as it unveiled that its listing, which valued the company at 21 mln stg, was close to three times over-subscribed. Shares in the medical support services firm, priced at 128 pence each, start trading on Aim August 20 and the company has raised 8.7 mln stg from its institutional placing, it said. The issue has been hailed as a major success by management, particularly given the current abject state of capital markets awash with telecoms paper and debt. And it exceeded chief executive Richard Steeves' hopes of netting 4-8 mln stg from the listing. Around 46 pct of the enlarged share capital has been placed with institutions, leaving the majority -- 53 pct -- in the hands of directors. Steeves, with a 19 pct stake valued at close to 4 mln stg, is the biggest single shareholder on the company. He founded it in 1991 along with non-executive director Andrew Fitton, who has 14 pct of the shares. Other big investors include chairman Clive Richards, who holds around 17 pct, and finance director Richard Pearson, with 2.4 pct. None of the executives have sold stock in the run up to the IPO and all agreed to a lock in agreement which prevents them from selling shares for the next year. Synergy, which provides waste management, theatre management, non-sterile and sterile services mainly to NHS Trusts, made an operating profit of 1.3 mln in the year to March 31, on sales of 10.7 mln. This represents a growth of 185 pct and 90 pct respectively over the last three years, it said. "Since announcing our intention to float on the alternative investment market in July we have been awarded additional new contracts taking the value book of our contracts to well over 40 mln," Steeves said. He added that Synergy's markets are "fast-growing and there is not very much competition." The company will use the proceeds from the listing to fund on-site technical service support units and a new multi-service facility in South East England. It will keep part of the proceeds as additional working capital. The listing is handled by Brewin Dolphin Securities. vh/ijl/tw For more information and to contact AFX: www.afxnews.com and www.afxpress.com |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
